Bipolar Disorder Market is poised to be USD 9.23Billionby 2025

The global Bipolar Disorder Market was valued at $5.8 Billion in 2017 and is forecast to grow at a modest 3.1 % CAGR between 2018 and 2025, culminating in 2025 global sales of $9.23 Billion.

Symptoms of bipolar disorder is a mental illness characterized by an extreme shift in mood, can include an extremely elevated mood called mania. It can have an episode of depression. People with bipolar disorder can have serious trouble managing daily life at office, school or work. As per the national institute of mental health (NIMH), 2.8% of U.S. adult have diagnosed with bipolar disorder and 4.4% have experienced at some time in their lives.

Based on drug class, the market is segmented as Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety. Usage of tricyclic antidepressants for bipolar disorder has declined over the years due to its side effect profile. More than 60% of the market is dominated by antipsychotic drugs such as Aripiprazole (Abilify), Asenapine (Saphris), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal) etc.

In 2017, North America was the leading region by revenue owing to factors such as thepresence of well-developed hospital and diagnostic center network, thehighrate of diagnosis, transparent process for availing reimbursement, and high emphasis on research & development. The U.S. alone accounts for over 80% share in North America.


There is a different type of Drugs for Bipolar Disorder such as:

  • Mood stabilizer
  • Anticonvulsant
  • Antipsychotic
  • Antidepressant
  • Antianxiety

The key market participants include Pfizer Inc., Janssen Pharmaceuticals, Glaxo SmithKline (GSK), AstraZeneca, Eli Lilly, Allergan Plc., Novartis AG, AbbVie Inc. and Otsuka Holdings Co. Ltd.


———>>> In-depth Analysis Report On Bipolar Disorder Market by Ameri Research Inc.

Global Bipolar Disorder Market Outlook To 2025: Key Drugs Class (Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety), Mechanism of Action (Dopaminergic neurotransmission inhibition, Selective serotonin reuptake inhibitor, Serotonin-norepinephrine reuptake inhibitor, Tricyclic antidepressants, Monoamine oxidase inhibitor, Benzodiazepines, Beta blockers, Others), Regional Segmentation, Competitive Dynamics, M&A Insights, Pricing Analysis (OPP, IPP, RAP), And Segment Forecast



Leave a Reply

Your email address will not be published. Required fields are marked *